Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, the company will utilize OT-101 (trabedersen), currently under investigation in mid-stage clinical trials with adult patients, for treating brain cancer and diffuse intrinsic pontine glioma.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mosaic ImmunoEngineering
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2024
Details:
Oncotelic lead product candidate, OT-101 is a TGF beta-2 inhibitor in combination with folfirinox. It is currently being evaluated in the Phase 2/3 clinical trial studies with patients for the treatment of Pancreatic Ductal Adenocarcinoma.
Lead Product(s): OT-101,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
OT-101, is a first-in-class anti-TGF-β2 RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer (metastatic pancreatic cancer) patients. TGF-β2 has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG.
Lead Product(s): OT-101
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
OT-101 - a TGF-β antisense- is active against recurrent glioblastoma in G004- a phase 2 clinical trial. OT-101 was delivered intratumorally by Convection Enhanced Delivery (CED).
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
OT-101 (trabedersen) has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG.
Lead Product(s): Trabedersen,Artemisinin
Therapeutic Area: Infections and Infectious Diseases Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 12, 2022
Details:
Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or superior to Remdesivir.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mateon Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
OT-101 (trabedersen) an antisense against TGF-β2 – for the treatment of solid tumors with focus on brain cancer in adult and DIPG in children. RPD for pediatric DIPG granted by US FDA.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
More than half of OT-101 (trabedersen) treated PC patients went into long term disease control (21 of 37 pts, 55%) allowing them to enter into subsequent chemotherapy which has an unexpected benefit of more than doubling their median OS, 9.3 vs. 2.6 mos, p<0.0001.
Lead Product(s): Trabedersen
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sapu Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
OT-101 (trabedersen), an antisense against TGF-β2 –for the treatment of various viruses, including the SARS and the current COVID-19, on its own and in conjunction with other compounds.
Lead Product(s): Trabedersen,Pembrolizumab
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2022